Precision BioSciences Q3 2023 net loss narrows to $8.1M; cash runway through 2025

PRECISION BIOSCIENCES INC

2023-Q3 EPS reported -$0.40 revenue$41,689,000

Q3 2023 revenue $13.1M (up from $7.4M YoY); net loss $8.1M ($0.07/share) vs $23.9M ($0.22/share) in Q3 2022.
Cash and equivalents $122.2M; expects runway through end of 2025, sufficient for Phase 1 data for lead in vivo programs.
Completed Imugene deal for azer-cel: $21M upfront plus potential $198M milestones and double-digit royalties.
PBGENE-HBV targeting CTA/IND in 2024; PBGENE-PMM targeting 2025; iECURE-OTC CTA/IND expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-059763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.